S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:ARWR

Arrowhead Pharmaceuticals - ARWR Earnings Date, Estimates & Call Transcripts

$35.29
+0.30 (+0.86%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$34.27
$35.88
50-Day Range
$28.00
$40.56
52-Week Range
$26.81
$56.25
Volume
767,956 shs
Average Volume
1.10 million shs
Market Capitalization
$3.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.22

Earnings Summary

Upcoming
Earnings Date
Feb. 6Confirmed
Actual EPS
(Nov. 28)
-$0.81 Missed By -$0.24
Consensus EPS
(Nov. 28)
-$0.57
Last Year's Q4 EPS
(11/22/2021)
-$0.61
Skip Charts & View Estimated and Actual Earnings Data

ARWR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ARWR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Arrowhead Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20235($0.81)$1.34$0.25 
Q2 20236($1.09)$0.16($0.73) 
Q3 20236($1.12)$0.15($0.73) 
Q4 20236($1.12)$0.15($0.77) 
FY 202323($4.14)$1.80 ($1.97)

ARWR Earnings Date and Information

Arrowhead Pharmaceuticals last announced its quarterly earnings data on November 28th, 2022. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.24. The business had revenue of $31.58 million for the quarter, compared to the consensus estimate of $107.60 million. Arrowhead Pharmaceuticals has generated ($1.68) earnings per share over the last year (($1.68) diluted earnings per share). Earnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($1.16) to ($2.47) per share. Arrowhead Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Monday, February 6th, 2023. Arrowhead Pharmaceuticals will be holding an earnings conference call on Monday, February 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call..

Arrowhead Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/6/2023
(Confirmed)
 $1.14       
11/28/2022Q4 2022($0.57)($0.81)($0.24)($0.81)$107.60 million$31.58 million
8/4/2022Q3 2022($0.45)($0.68)($0.23)($0.68)$52.61 million$32.41 million    
5/10/2022Q2 2022$0.39$0.41+$0.02$0.41$122.15 million$151.80 million    
2/2/2022Q1 2022($0.22)($0.60)($0.38)($0.60)$67.30 million$27.44 million    
11/22/20219/30/2021$0.04($0.61)($0.65)($0.61)$79.31 million$38.28 million    
8/4/20216/30/2021($0.08)($0.29)($0.21)($0.29)$50.20 million$45.89 million    
5/3/20213/31/2021($0.09)($0.26)($0.17)($0.26)$39.42 million$32.81 million  
2/3/202112/31/2020$1.00($0.20)($1.20)($0.20)$157.48 million$21.30 million  
11/22/20209/30/2020$0.34($0.48)($0.82)($0.48)$85.13 million$7.63 million  
8/5/20206/30/2020($0.07)($0.13)($0.06)($0.13)$38.76 million$27.38 million  
5/7/20203/31/2020($0.11)($0.20)($0.09)($0.20)$21.90 million$23.53 million  
2/5/202012/31/2019$0.04($0.03)($0.07)($0.03)$36.63 million$29.46 million  
11/25/2019Q4$0.14$0.11($0.03)$0.11$36.97 million$43.29 million  
8/5/2019Q3 2019$0.34$0.21($0.13)$0.21$59.05 million$42.70 million  
5/8/20193/31/2019$0.22$0.24+$0.02$0.24$45.78 million$48.15 million  
2/7/201912/31/2018$0.76$0.13($0.63)$0.13$90.88 million$34.66 million
12/11/2018Q4 2018($0.17)($0.12)+$0.05($0.12)$3.73 million$11.26 million  
8/7/2018Q3 2018($0.19)($0.18)+$0.01($0.18)$0.62 million$0.73 million
5/8/2018Q2 2018($0.19)($0.18)+$0.01($0.18)$4.04 million$0.65 million
2/9/2018Q1 2018($0.14)($0.18)($0.04)($0.18)$8.71 million$3.51 million  
12/12/2017Q4 2017($0.12)($0.14)($0.02)($0.14)$7.32 million$8.71 million
8/3/2017Q3 2017($0.13)($0.07)+$0.06($0.07)$5.29 million$9.34 million  
5/3/2017Q2 2017($0.1230)($0.08)+$0.0430($0.08)$4.19 million$8.99 million  
2/6/2017Q117($0.20)($0.17)+$0.03($0.17)$13.24 million$4.37 million  
12/14/2016Q4 2016($0.33)($0.31)+$0.02($0.28)$0.04 million$0.03 million
8/9/2016Q316($0.37)($0.32)+$0.05($0.32)$0.05 million$39.58 million
5/10/2016Q216($0.37)($0.35)+$0.02($0.35)$0.26 million$0.04 million  
2/9/2016Q1($0.41)($0.32)+$0.09($0.32)$0.29 million$0.04 million
12/14/2015Q415($0.39)($0.42)($0.03)($0.42)$0.14 million$0.04 million  
8/4/2015Q315($0.38)($0.27)+$0.11($0.27)$0.11 million$0.12 million
5/11/2015Q214($0.35)($0.33)+$0.02($0.15)$110.00 million$43.75 million  
2/9/2015Q114($0.32)($0.41)($0.09)($0.41)$0.24 million$0.17 million
11/25/2014Q413($0.25)($0.33)($0.08)($0.24)$0.04 million$0.04 million  
8/12/2014Q313($0.22)($0.22)($0.22)$0.04 million$0.04 million  
5/6/2014Q2 2014($0.18)($0.31)($0.13)($0.31)$0.05 million$0.04 million
2/4/2014Q1 2014($0.18)($0.28)($0.10)($0.28)$0.05 million$0.04 million
12/18/2013Q4($0.23)($0.43)($0.20)  
8/7/2013Q3 2013($0.22)($0.23)($0.01)($0.23)$0.50 million$0.04 million
5/9/2013Q2 2013($0.41)($0.41)($0.41)$0.04 million  
2/13/2013Q1 2013($0.33)($0.33)  
12/20/2012Q4 2012($0.43)($0.43)
8/13/2012Q3 2012($0.71)($0.71)($0.71)
5/8/2012Q2 2012($0.44)($0.44)($0.38)
2/9/2012Q1 2012($0.25)($0.25)($0.25)
12/20/2011Q4 2011($0.39)($0.39)($0.39)
8/8/2011Q3 2011($0.20)($0.26)($0.06)($0.27)
5/12/2011Q2 2011($0.20)($0.18)+$0.02($0.73)
2/10/2011Q1 2011($0.20)($0.20)($0.20)
12/22/2010Q4 2010($0.30)($0.28)+$0.02($0.28)
8/12/2010Q3 2010($0.50)($0.06)+$0.44($0.06)
5/13/2010Q2 2010($0.40)($0.33)+$0.07($0.33)
2/11/2010Q1 2010($0.30)($0.30)($0.30)
12/22/2009Q4 2009($0.60)($0.60)($0.60)
8/10/2009Q3 2009($0.60)($0.60)($0.60)
5/15/2009Q2 2009($1.20)($1.20)($1.20)
2/9/2009Q1 2009($1.90)($1.90)($1.90)
12/15/2008Q4 2008($2.14)($2.14)($2.14)
8/11/2008Q3 2008($1.90)($1.90)($1.90)
2/11/2008Q1 2008($1.40)($1.40)($1.40)












Arrowhead Pharmaceuticals Earnings - Frequently Asked Questions

When is Arrowhead Pharmaceuticals's earnings date?

Arrowhead Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Monday, February 6th, 2023. Learn more on ARWR's earnings history.

Did Arrowhead Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) missed the analysts' consensus estimate of ($0.57) by $0.24 with a reported earnings per share (EPS) of ($0.81). Learn more on analysts' earnings estimate vs. ARWR's actual earnings.

How much revenue does Arrowhead Pharmaceuticals generate each year?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded annual revenue of $243.23 million.

How much profit does Arrowhead Pharmaceuticals generate each year?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded net income of -$176.06 million. ARWR has generated -$1.68 earnings per share over the last four quarters.

What is Arrowhead Pharmaceuticals's EPS forecast for next year?

Arrowhead Pharmaceuticals's earnings are expected to decrease from ($1.16) per share to ($2.47) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:ARWR) was last updated on 2/2/2023 by MarketBeat.com Staff